ANG-First Trial (Angiotensin II as First-Line Vasopressor Therapy in Cardiac Surgery)
Recruiting · Phase 4 · NCT06487585
Conditions: Vasodilatory Hypotension During or After Cardiac Surgery
At a glance
- Research payments reported, 2025
- $241,944
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 100
About the trial
- Sponsor
- University of Maryland St. Joseph Medical Center (with La Jolla Pharmaceutical Company)
- Tested
- Angiotensin II (drug)
- Dates
- Started 2025-05-06; completion 2026-02
- Results posted
- Not yet
The purpose of this research is to evaluate the use of Angiotensin II in patients with low blood pressure post-surgery. Your information will be collected for 28 days post the procedure and initiation of the study drug to assess for safety events and complications.
From ClinicalTrials.gov, last updated 2025-12-22. Full record, eligibility and contacts (opens in a new tab)
Industry funding
La Jolla Pharmaceutical Company reported $241,944 in research payments for this study in 2025 (11 payments).
Products named: Giapreza
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- University of Maryland St Joseph Medical Center $241,944
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.